Serostatus: Difference between revisions
Content deleted Content added
m cleanup using AWB |
Citation bot (talk | contribs) Add: doi-access. | Use this bot. Report bugs. | #UCB_CommandLine |
||
| (17 intermediate revisions by 14 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Presence of a marker in blood}} |
|||
'''Serostatus''' refers to the presence or absence of a [[serological]] marker in the blood. The presence of detectable levels of a specific marker within the [[serum (blood)|serum]] is considered '''seropositivity''', while the absence of such levels is considered '''seronegativity'''. |
'''Serostatus''' refers to the presence or absence of a [[serological]] marker in the blood. The presence of detectable levels of a specific marker within the [[serum (blood)|serum]] is considered '''seropositivity''', while the absence of such levels is considered '''seronegativity'''. |
||
==HIV/AIDS== |
==HIV/AIDS== |
||
The term serostatus is commonly used in HIV/AIDS prevention efforts. In |
The term serostatus is commonly used in HIV/AIDS prevention efforts. In the late 20th and early 21st centuries, social advocacy has emphasized the importance of learning one's HIV/AIDS serostatus in an effort to curtail the spread of the disease.<ref name=SAFE /> |
||
==Autoimmune disease== |
==Autoimmune disease== |
||
| Line 8: | Line 9: | ||
==See also== |
==See also== |
||
*[[ |
* [[Seroconversion]] |
||
* [[Correlates of immunity]] |
|||
==References== |
==References== |
||
{{reflist | refs= |
{{reflist | refs= |
||
<ref name=SAFE>{{cite journal | |
<ref name=SAFE>{{cite journal | last1=Janssen | first1=Robert S. | last2=Holtgrave | first2=David R. | last3=Valdiserri | first3=Ronald O. | last4=Shepherd | first4=Melissa | last5=Gayle | first5=Helene D. | last6=De Cock | first6=Kevin M. | display-authors=3 | date=July 2001 | title=The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals | journal=American Journal of Public Health | publisher=American Public Health Association | volume=91 | issue=7 | pages=1019–1024 | doi=10.2105/AJPH.91.7.1019 | issn=1541-0048 | pmc=1446705 | pmid=11441723 |name-list-style=vanc}}</ref> |
||
<ref name=Neuromyelitis>{{cite journal | |
<ref name=Neuromyelitis>{{cite journal | last1=Jarius | first1=Sven | last2=Ruprecht | first2=Klemens | last3=Wildemann | first3=Brigitte | last4=Kuempfel | first4=Tania | last5=Ringelstein | first5=Marius | last6=Geis | first6=Christian | last7=Kleiter | first7=Ingo | last8=Kleinschnitz | first8=Christoph | last9=Berthele | first9=Achim | last10=Brettschneider | first10=Johannes | last11=Hellwig | first11=Kerstin | last12=Hemmer | first12=Bernhard | last13=Linker | first13=Ralf A | last14=Lauda | first14=Florian | last15=Mayer | first15=Christoph A | last16=Tumani | first16=Hayrettin | last17=Melms | first17=Arthur | last18=Trebst | first18=Corinna | last19=Stangel | first19=Martin | last20=Marziniak | first20=Martin |last21=Hoffman | first21=Frank | last22=Schippling | first22=Sven | last23=Faiss | first23=Jurgen H | last24=Neuhaus | first24=Oliver | last25=Ettrich | first25=Barbara | last26=Zentner | first26=Christian | last27=Guthke | first27=Kersten | last28=Hofstadt-van Oy | first28=Ulrich | last29=Reuss | first29=Reinhard | last30=Pellkofer | first30=Hannah | last31=Ziemann | first31=Ulf | last32=Kern | first32=Peter | last33=Wandinger | first33=Klaus P | last34=Bergh | first34=Florian Then | last35=Boettcher | first35=Tobias | last36=Langel | first36=Stefan | last37=Liebetrau | first37=Martin | last38=Rommer | first38=Paulus S | last39=Niehaus | first39=Sabine | last40=Munch | first40=Christoph | last41=Winkelmann | first41=Alexander | last42=Zettl U | first42=Uwe K | last43=Metz | first43=Imke | last44=Veauthier | first44=Christian | last45=Sieb | first45=Jorn P | last46=Wilke | first46=Christian | last47=Hartung | first47=Hans P | last48=Aktas | first48=Orhan | last49=Paul | first49=Friedemann | display-authors=3 | date=January 2012 | title=Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients | journal=Journal of Neuroinflammation | publisher=BioMed Central | volume=9 | issue=1 | pages=14 | doi=10.1186/1742-2094-9-14 | pmc=3283476 | pmid=22260418 |name-list-style=vanc | doi-access=free }}</ref> |
||
<ref name=Rheumatoid>{{cite journal | |
<ref name=Rheumatoid>{{cite journal | last1=Ajeganova | first1=Sofia | last2=Huizinga | first2=Tom W J | date=November 2014 | title=Rheumatoid arthritis: Seronegative and seropositive RA: alike but different? | journal=Nature Reviews Rheumatology | publisher=Nature Publishing Group | volume=11 | issue=1 | pages=8–9 | doi=10.1038/nrrheum.2014.194 | issn=1759-4804 | pmid=25403158 | s2cid=1405551 |name-list-style=vanc}}</ref> |
||
<ref name=Pancreatitis>{{cite journal | |
<ref name=Pancreatitis>{{cite journal | last1=Balasubramanian | first1=Gokulakrishnan | last2=Sugumar | first2=Aravind | last3=Smyrk | first3=Thomas C | last4=Takahashi | first4=Naoki | last5=Clain | first5=Jonathan E | last6=Gleeson | first6=Ferga C | last7=Hart | first7=Phil A | last8=Levy | first8=Michael J | last9=Pearson | first9=Randall K | last10=Petersen | first10=Bret T | last11=Topazian | first11=Mark D | last12=Vege | first12=Santhi S | last13=Chari | first13=Suresh T | display-authors=3 | year=2012 | title=Demystifying seronegative autoimmune pancreatitis | url=http://www.pancreatology.net/article/S1424-3903%2812%2900129-9/abstract | journal=Pancreatology | publisher=Elsevier | volume=12 | issue=4 | pages=289–294 | doi=10.1016/j.pan.2012.05.003 | pmid=22898628 |name-list-style=vanc}}</ref> |
||
<ref name=Novel>{{cite journal | |
<ref name=Novel>{{cite journal | last1=Somers | first1=Klaartje | last2=Geusens | first2=Piet | last3=Elewaut | first3=Dirk | last4=De Keyser | first4=Filip | last5=Rummens | first5=Jean-Luc | last6=Coenen | first6=Marieke | last7=Blom | first7=Marlies | last8=Stinissen | first8=Piet | last9=Veerle | first9=Somers | display-authors=3 | date=February 2011 | title=Novel autoantibody markers for early and seronegative rheumatoid arthritis | journal=Journal of Autoimmunity | publisher=Elsevier | volume=36 | issue=1 | pages=33–46 | doi=10.1016/j.jaut.2010.10.003 | issn=0896-8411 | pmid=21071175 |name-list-style=vanc}}</ref> |
||
<ref name=Myasthenia>{{cite journal | |
<ref name=Myasthenia>{{cite journal | last1=Pevzner | first1=Alexandra | last2=Schoser | first2=Benedikt | last3=Peters | first3=Katja | last4=Cosma | first4=Nicoleta-Carmen | last5=Karakatsani | first5=Andromachi | last6=Schalke | first6=Berthold | last7=Melms | first7=Arthur | last8=Kroger | first8=Stephan | display-authors=3 | date=August 2011 | title=Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis | url=https://www.researchgate.net/publication/51545644 | format=PDF | journal=Journal of Neurology | publisher=Springer-Verlag | volume=259 | issue=3 | pages=427–435 | doi=10.1007/s00415-011-6194-7 | issn=1432-1459 | pmid=21814823 | s2cid=13125248 |name-list-style=vanc}}</ref>}} |
||
{{HIV and AIDS}} |
|||
[[Category:Serology]] |
[[Category:Serology]] |
||
[[Category:HIV/AIDS]] |
|||
Latest revision as of 00:15, 4 December 2023
Serostatus refers to the presence or absence of a serological marker in the blood. The presence of detectable levels of a specific marker within the serum is considered seropositivity, while the absence of such levels is considered seronegativity.
HIV/AIDS
[edit]The term serostatus is commonly used in HIV/AIDS prevention efforts. In the late 20th and early 21st centuries, social advocacy has emphasized the importance of learning one's HIV/AIDS serostatus in an effort to curtail the spread of the disease.[1]
Autoimmune disease
[edit]Researchers have investigated the effects of autoantibody serostatus on autoimmune disease presentation.[2][3][4] Study of seronegative patient populations has led to the identification of additional autoantibodies that could potentially help with diagnosis.[5][6]
See also
[edit]References
[edit]- ^ Janssen RS, Holtgrave DR, Valdiserri RO, et al. (July 2001). "The Serostatus Approach to Fighting the HIV Epidemic: prevention strategies for infected individuals". American Journal of Public Health. 91 (7). American Public Health Association: 1019–1024. doi:10.2105/AJPH.91.7.1019. ISSN 1541-0048. PMC 1446705. PMID 11441723.
- ^ Jarius S, Ruprecht K, Wildemann B, et al. (January 2012). "Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients". Journal of Neuroinflammation. 9 (1). BioMed Central: 14. doi:10.1186/1742-2094-9-14. PMC 3283476. PMID 22260418.
- ^ Ajeganova S, Huizinga TW (November 2014). "Rheumatoid arthritis: Seronegative and seropositive RA: alike but different?". Nature Reviews Rheumatology. 11 (1). Nature Publishing Group: 8–9. doi:10.1038/nrrheum.2014.194. ISSN 1759-4804. PMID 25403158. S2CID 1405551.
- ^ Balasubramanian G, Sugumar A, Smyrk TC, et al. (2012). "Demystifying seronegative autoimmune pancreatitis". Pancreatology. 12 (4). Elsevier: 289–294. doi:10.1016/j.pan.2012.05.003. PMID 22898628.
- ^ Somers K, Geusens P, Elewaut D, et al. (February 2011). "Novel autoantibody markers for early and seronegative rheumatoid arthritis". Journal of Autoimmunity. 36 (1). Elsevier: 33–46. doi:10.1016/j.jaut.2010.10.003. ISSN 0896-8411. PMID 21071175.
- ^ Pevzner A, Schoser B, Peters K, et al. (August 2011). "Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis" (PDF). Journal of Neurology. 259 (3). Springer-Verlag: 427–435. doi:10.1007/s00415-011-6194-7. ISSN 1432-1459. PMID 21814823. S2CID 13125248.